China Dasheng Biotechnology Company
Cycclone Inc., together with its subsidiaries, engages in the production, marketing, and distribution of bacteria based products used as additives for livestock feed and crop cultivation in the People's Republic of China. It provides artificial microorganisms (AM) and high-efficiency microorganism (HM) based biological bacterium blends; and biological preservatives. The company offers AM/HM bacte… Read more
China Dasheng Biotechnology Company (CDBT) - Net Assets
Latest net assets as of December 2024: $-755.75K USD
Based on the latest financial reports, China Dasheng Biotechnology Company (CDBT) has net assets worth $-755.75K USD as of December 2024.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($420.22K) and total liabilities ($1.18 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-755.75K |
| % of Total Assets | -179.85% |
| Annual Growth Rate | N/A |
| 5-Year Change | -111.59% |
| 10-Year Change | N/A |
| Growth Volatility | 0.24 |
China Dasheng Biotechnology Company - Net Assets Trend (2006–2023)
This chart illustrates how China Dasheng Biotechnology Company's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for China Dasheng Biotechnology Company (2006–2023)
The table below shows the annual net assets of China Dasheng Biotechnology Company from 2006 to 2023.
| Year | Net Assets | Change |
|---|---|---|
| 2023-06-30 | $-1.21 Million | -3946.02% |
| 2022-06-30 | $-30.00K | -100.17% |
| 2008-06-30 | $17.26 Million | +25507.43% |
| 2007-10-31 | $-67.93K | -100.65% |
| 2007-06-30 | $10.48 Million | +2749576.38% |
| 2006-06-30 | $-381.00 | -- |
Equity Component Analysis
This analysis shows how different components contribute to China Dasheng Biotechnology Company's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 146077700.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (June 2023)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $40.98K | % |
| Other Comprehensive Income | $48.68K | % |
| Other Components | $166.80K | % |
| Total Equity | $-1.21 Million | 100.00% |
China Dasheng Biotechnology Company Competitors by Market Cap
The table below lists competitors of China Dasheng Biotechnology Company ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
AFRICA EATS LTD (USD)
SEM:EATS
|
$560.06 |
|
TANFIELD GRP
BE:XS3A
|
$560.30 |
|
Gateway Bank F.S.B.
PINK:GWBK
|
$561.38 |
|
TALISMAN MINING (RJA.SG)
STU:RJA
|
$561.44 |
|
Veltex Corporation
OTCQB:VLXC
|
$559.32 |
|
Egyptian Arabian(Themar)Comp. For Securities&Bonds Brok. EAC
EGX:EASB
|
$557.12 |
|
Xebra Brands Ltd
OTCQB:XBRAF
|
$556.66 |
|
PP LONDON SUMATRA (PS9A.SG)
STU:PS9A
|
$555.60 |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in China Dasheng Biotechnology Company's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2022 to 2023, total equity changed from -30,000 to -1,213,806, a change of -1,183,806.
- Net loss of 967,000 reduced equity.
- Other comprehensive income increased equity by 48,678.
- Other factors decreased equity by 265,484.
Equity Change Factors (2022 to 2023)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-967.00K | -79.67% |
| Other Comprehensive Income | $48.68K | +4.01% |
| Other Changes | $-265.48K | -21.87% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares China Dasheng Biotechnology Company's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2006-06-30 | $0.00 | $0.06 | x |
| 2008-06-30 | $0.52 | $0.06 | x |
| 2022-06-30 | $0.00 | $0.06 | x |
| 2023-06-30 | $-0.03 | $0.06 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently China Dasheng Biotechnology Company utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is below the historical average (10.27%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2006 | 0.00% | -3.48% | 9.93x | 0.00x | $-16.83K |
| 2007 | 21.81% | 19.99% | 0.65x | 1.69x | $1.08 Million |
| 2007 | 0.00% | 0.00% | 0.00x | 0.00x | $-61.65K |
| 2008 | 29.55% | 28.46% | 0.80x | 1.29x | $3.07 Million |
| 2023 | 0.00% | 0.00% | 0.00x | 0.00x | $-845.62K |
Industry Comparison
This section compares China Dasheng Biotechnology Company's net assets metrics with peer companies in the Shell Companies industry.
Industry Context
- Industry: Shell Companies
- Average net assets among peers: $36,677,338
- Average return on equity (ROE) among peers: -64.57%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| China Dasheng Biotechnology Company (CDBT) | $-755.75K | 0.00% | N/A | $559.38 |
| Artius II Acquisition Inc. Class A Ordinary Shares (AACB) | $-60.27K | 0.00% | 0.00x | $198.37 Million |
| Artius II Acquisition Inc. Units (AACBU) | $-60.27K | 0.00% | 0.00x | $205.28 Million |
| Ares Acquisition Corporation II (AACT-UN) | $931.34 Million | 0.00% | 0.08x | $399.77 Million |
| AA Mission Acquisition Corp. (AAM-UN) | $-559.90 Million | 0.00% | 0.00x | $349.76 Million |
| Global Acquisitions Corporation (AASP) | $3.80 Million | -5.26% | 0.34x | $15.42 Million |
| ABV Consulting Inc (ABVN) | $8.75K | -623.31% | 2.50x | $461.96K |
| Atlantic Coastal Acquisition Corp II (ACAB) | $-8.52 Million | 0.00% | 0.00x | $2.44 Million |
| Annabidiol Corp (ACBD) | $-501.57K | 0.00% | 0.00x | $13.62K |
| ACRO Biomedical Co Ltd (ACBM) | $685.87K | -17.12% | 0.46x | $30.04K |
| Huaizhong Health Group Inc (ADAD) | $-19.47K | 0.00% | 0.00x | $3.15K |